Biosergen Releases Interview with Principal Investigator Dr. Pawan Singh on Drug-Resistant Fungal Infections and BSG005
November 21, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, is pleased to announce the release of a fireside-chat-style video interview during the World Antimicrobial Resistance Awareness Week (WAAW). The video features the company’s CEO, Tine Olesen, in conversation with Dr. Pawan Kumar Singh, Principal Investigator of Biosergen’s ongoing proof-of-concept trial for BSG005. The video is now available on the company’s website: https://www.biosergen.net/investor-relations#Events,%20Presentations,%20Media
“I thoroughly enjoyed this conversation with Dr. Singh, whose expertise and dedication are invaluable to our BSG005 trial,” said Tine Olesen, CEO of Biosergen. “His on-the-ground insights into the complexities of life-threatening fungal infections offer a greater understanding of how BSG005 may play a key role in addressing some of the challenges clinical practitioners face today. By sharing this conversation, we aim to provide all of Biosergen’s stakeholders with the highest level of transparency into our ongoing trial, and we hope is also contributes to the general awareness of antimicrobial resistance during this week.”
World Antimicrobial Resistance Awareness Week, observed from November 18 to November 24, is supported by global organizations such as the World Health Organization (WHO), the Food and Agriculture Organization (FAO), and the UN Environment Programme (UNEP). The week is meant to emphasize the urgent need for global action to combat drug-resistant infections, including fungal infections where resistance is growing.
Dr. Singh, an associate professor and renowned specialist in pulmonary, lung cancer and critical care medicine, heads the Thoracic Oncology Clinic at Pt BDS Post Graduate Institute of Medical Sciences, University of Health Sciences in Rohtak, Haryana, India.
In the video, Dr. Singh touches on the rising incidence of invasive fungal infections in India, where resistance to existing therapies poses a significant challenge. Biosergen’s antifungal candidate, BSG005, is designed to address this gap. Unlike many treatments, BSG005 kills fungi outright rather than merely inhibiting their growth. Similar to amphotericin B, which has been used for decades without notable resistance, BSG005 is likely to exhibit the same durability against resistance but without severe side effects, making it a potentially promising tool in the global fight against antimicrobial resistance in fungal infections.
The video was recorded at a trial site in India before the completion of the first cohort in Biosergen’s trial and does not introduce new material information. However, it provides viewers with a more thorough understanding of Biosergen's ongoing work and the challenging tasks that clinical professionals face daily in combating fungal infections.
Link to the WHO’s World Antimicrobial Resistance Awareness Week campaign site:
